Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration [8] (multiple letters)

Journal of Urology

Volumn 162, Issue 1, 1999, Pages 170-171

  Oefelein, M G ^a   Dearnaley, D P ^a   Norman, A R ^a   Shahidi, M ^a   Meinhardt, W ^a   Horenblas, S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE;

ADULT; AGED; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LETTER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL; ADJUVANT THERAPY; BLOOD; DRUG ADMINISTRATION; NOTE; PROSTATE TUMOR; TIME;

ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 34548519197     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199907000-00058     Document Type: Letter

References (1)

1. Kisman O.K. de Voogt H.J. Baak J.A. Reversibility of the effect of LHRH agonists and other antiandrogenic hormones on the testis: a histomorphometric study Eur. Urol. 18 1990 299